Where is Xterna located?

Xterna is headquartered in London, United Kingdom.

Where does Xterna rank among its competitors?

Xterna ranks 7th amongst 6 active competitors, of which 2 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Panarum, which secured an undisclosed amount in Feb, 2025.

Who are the top competitors of Xterna?

Xterna's top competitors include Xias Bio, Transcera Bio and Panarum. Among them, Panarum secured the most recent funding round in February, 2025.

Xterna - 2026 Company Profile & Competitors

Xterna is an unfunded company based in London (United Kingdom), founded in 2024. It operates as a Developer of enhanced nucleic acids for targeted drug delivery solutions. Xterna has not raised any funding yet. The company has 6 active competitors, including 2 that are funded. Its top competitors include companies like Xias Bio, Transcera Bio and Panarum.

Company Details

Developer of enhanced nucleic acids for targeted drug delivery solutions. It focuses on revolutionising the delivery of drugs to specific targets within the body. The company uses its technology to make previously untreatable conditions curable. It is supported by multiple organisations and universities.

Key Metrics

Founded Year

2024

Location

London, United Kingdom

Stage

Unfunded

Ranked

7^th among 7 competitors

Similar Companies

Xias Bio & 5 more

View Xterna's full profile

Xterna has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xterna include Xias Bio, Transcera Bio and Panarum. Here is the list of Top 10 competitors of Xterna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Xias Bio 2020, United States, Seed	Developer of recombinant proteins	$5.23M	IndieBio, SOSV & 4 others	38/100
2nd	Transcera Bio 2021, Boston (United States), Funding Raised	Developer of biologic therapeutics for chronic diseases	-	Tau Ventures, Pear VC	36/100
3rd	Panarum 2016, Buenos Aires (Argentina), Seed	Developer of gastroprotectans oral drug delivery device	$640K	Village Capital, Draper Cygnus & 1 others	31/100
4th	Neuronano Pharma 2011, Chapel Hill (United States), Funding Raised	Developer of formulation and drug delivery technologies	-	HHS	23/100
5th	Procure Bio Unfunded	Developer of gene and protein therapeutics for genetic diseases	-	-	16/100
6th	Global BioTherapeutics 2009, San Diego (United States), Deadpooled	Developer of a gene delivery platform to treat genetic diseases and chronic illnesses	-	-	16/100
7th	Xterna 2024, London (United Kingdom), Unfunded	Developer of enhanced nucleic acids for targeted drug delivery solutions	-	-	-